InvestorsHub Logo
Followers 12
Posts 801
Boards Moderated 0
Alias Born 02/09/2013

Re: gta888 post# 5563

Sunday, 11/03/2013 4:27:02 PM

Sunday, November 03, 2013 4:27:02 PM

Post# of 48316
Just my opinion and others' may differ but I see oncosec as having far less potential than inovio. Inovio licenses the electroporation tech to oncs (oncs doesn't own it and they do pay for the license) and Inovio also has a deep pipeline with their syncon synthetic dna platform developing dna-based vaccines to be delivered via electroporation. Oncs's lead trials are delivering interleukin (a compound they don't own) via electroporation (using devices they don't own).

Based on the clinical work to date between oncs, ino and others using different ep devices, my opinion is that the 2007 piii failure had more to do with what they were delivering (the antibiotic bleomycin) than the ep tech itself. The interleukin used in the current trials is not a mere antibiotic (it regulates communication between cells) and does have a long track record of having some efficacy treating cancer. The problem with systemic delievery of interleukin is very nasty adverse effects. If the use of ep to deliver it locally rather than systemically can avoid AE's as much as has been suggested by the early data to date, without reducing its previous effiacy, then the stock should do quite well compared to current levels.

Long run, imo, it does not have nearly potential of ino, but is worth buying a few shares at the current bargain price.

Again, in case I didn't say it enough yet, this is just my opinion.